Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model

Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model

Purpose: Vascular targeted photodynamic therapy (VTP) is a nonsurgical tumor ablation approach used to treat early-stage prostate cancer and may also be effective for upper tract urothelial cancer (UTUC) based on preclinical data. Toward increasing response rates to VTP, we evaluated its efficacy in...

Full description

Bibliographic Details
Main Authors: Ricardo G. Alvim, Petrina Georgala, Lucas Nogueira, Alexander J. Somma, Karan Nagar, Jasmine Thomas, Laura Alvim, Amelia Riegel, Christopher Hughes, Jie Chen, Augusto B. Reis, Souhil Lebdai, Avigdor Scherz, Steven Zanganeh, Rui Gardner, Kwanghee Kim, Jonathan A. Coleman
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Molecules
Subjects:
bladder cancer
tumor ablation
TOOKAD
focal therapy
immunotherapy
Online Access:https://www.mdpi.com/1420-3049/26/12/3744

Internet

https://www.mdpi.com/1420-3049/26/12/3744

Similar Items